Inspira Technologies Announces Strategic Shift To Accelerate Commercialization Of FDA-Cleared INSPIRA ART100 System, While Maintaining Development, Regulatory Pathways Of Its Portfolio

Benzinga · 05/29 13:17

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic shift to accelerate the commercialization of its U.S. FDA (Food and Drug Administration)-cleared INSPIRA™ ART100 system (the "ART100"), while maintaining the development and regulatory pathways of its portfolio of products. The Company is currently engaged in active sales discussions in multiple locations.

This development follows the initial clinical implementation of the ART100 system in medical centers in the U.S., where the device has been used to treat patients in real-world clinical settings.